Life Sciences and Healthcare in Europe

Life Sciences and Healthcare in Europe

You are currently viewing Dentons' capabilities in Life Sciences and Healthcare in Europe. To view capabilities in other regions please select below:

{CF6B9E3C-95E6-4396-AAD8-58113FC78C50}

Regional Capabilities

The life sciences and healthcare field is defined by numerous features: strong growth, constant innovation, long-term cycles of development, increasing international competition and complex financing. All of them require personalized and adapted solutions, with advice that is goal-oriented and cost-effective.

Dentons’ Life Sciences and Healthcare group in Europe understands the scientific and economic tools and data necessary to provide you with effective legal guidance on complex issues. You can rely on our carefully selected teams of specialists who have many years of involvement in the life sciences and healthcare industries.

Our lawyers have a wealth of experience and are recognized leading legal advisors to health practitioners and businesses, including to organizations with business interests in the life sciences and health and pharmaceuticals sector. We advise you on the complete range of services and considerations, including:

Competition
Corporate and commercial law
Dispute resolution and arbitration
Distribution
Employment law
Intellectual property and patent advice
Regulatory law
M&A
Tax

It is crucial for your business to find relevant and solid legal advice to optimize the return on your investments and achieve your business goals—whether your business is a public or private player, a medical or biological institution, a manufacturer, distributor or a service provider in the life sciences and health care sector, you face a wide array of multifaceted challenges.

Our teams offer tailored assistance and in-depth knowledge of relevant products and activities, and we provide quick responses to urgent situations. We can also structure complex licensing, distribution, co-promotion, development and manufacturing agreements to help you keep your projects moving, while mitigating risks.

When it comes to life sciences and healthcare law and advice throughout Europe, look no further than Dentons.

Recognition

Dentons wins four awards at the MF Legal Rankings 2023

May 15, 2023

Dentons was honored with four awards at Class Editori’s “MF Legal Rankings 2023.”

Dentons wins four awards at TopLegal Industry Awards 2022

May 13, 2022

Dentons was awarded “Law Firm of the year—Life Sciences” and “Law Firm of the year—Technology,” while Italy Managing Partner Federico Sutti was named “Lawyer of the year—Real Estate” and Partner Giangiacomo Olivi was named “Lawyer of the year—Media” at the TopLegal Industry Awards 2022. This year, the awards ceremony took place in Milan on May 10, 2022.

Dentons named Financial & Corporate Firm of the Year: Corporate at the 2020 LMG European Life Sciences Awards

June 11, 2020

We are pleased to announce that the 2020 LMG European Life Sciences recognized Dentons as the winner in the Financial & Corporate Firm of the Year: Corporate category.

View all recognition for Life Sciences and Healthcare in Europe

Insights

Ukraine introduces new benefits for voluntary tax compliance

September 30, 2024

Ukraine: Commencing from October 1, 2024, tax benefits for taxpayers with a high level of voluntary tax compliance or members of the announced “White Business Club” will come into full force and effect.

Life Sciences Legal Update - Q1 2024

March 27, 2024

Czech Republic: We bring you the first 2024 edition of the quarterly Life Science Legal Update, in which we regularly cover key legal aspects and innovations in the Pharmaceuticals and Life Sciences sectors. The first quarter of 2024 is full of news in the pharmaceutical, healthcare services and food sectors. For instance, there has been much discussion about limiting the availability of HHC substances to consumers; in addition, several implementing regulations for the amendment to the Medicines Act have come into force as well as a new pricing regulation under which health insurers will now be able to request a maximum price for a specific medicinal product as part of an exceptional reimbursement regime. The EU is about to negotiate the draft pharmaceutical package presented by the European Commission. Last but not least, the major amendment to the Significant Market Power Act which has been newly effected, and which largely affects buyer-supplier relationships in the supply of food, agricultural products and other related services.